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required for the development of disease
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Background: Enteric pathogens utilize a distinct set of proteins to modulate host cell signaling events that
promote host cell invasion, induction of the inflammatory response, and intracellular survival. Human infection with
Campylobacter jejuni, the causative agent of campylobacteriosis, is characterized by diarrhea containing blood and
leukocytes. The clinical presentation of acute disease, which is consistent with cellular invasion, requires the delivery
of the Campylobacter invasion antigens (Cia) to the cytosol of host cells via a flagellar Type III Secretion System
(T3SS). We identified a novel T3SS effector protein, which we termed CiaD that is exported from the C. jejuni
flagellum and delivered to the cytosol of host cells.
Results: We show that the host cell kinases p38 and Erk 1/2 are activated by CiaD, resulting in the secretion of
interleukin-8 (IL-8) from host cells. Additional experiments revealed that CiaD-mediated activation of p38 and Erk 1/
2 are required for maximal invasion of host cells by C. jejuni. CiaD contributes to disease, as evidenced by infection
of IL-10 knockout mice. Noteworthy is that CiaD contains a Mitogen-activated protein (MAP) kinase-docking site
that is found within effector proteins produced by other enteric pathogens. These findings indicate that C. jejuni
activates the MAP kinase signaling pathways Erk 1/2 and p38 to promote cellular invasion and the release of the
IL-8 pro-inflammatory chemokine.
Conclusions: The identification of a novel T3SS effector protein from C. jejuni significantly expands the knowledge
of virulence proteins associated with C. jejuni pathogenesis and provides greater insight into the mechanism
utilized by C. jejuni to invade host cells.
Keywords: Invasion, Erk 1/2, p38, IL-8 secretion, Type III secretion systemLay abstract
In contrast to the conventional view that the flagellum is
only used for bacterial motility, Campylobacter jejuni
also uses the flagellum as a Type III Secretion System
(T3SS). A subset of proteins exported from the flagellum
are delivered to the cytosol of host cell, where they modify
host cell signaling events to the benefit of the bacterial
pathogen. Here we report that C. jejuni, which is the
leading bacterial cause of food-borne disease worldwide,
possesses a novel T3SS virulence protein that we termed
CiaD. We show that CiaD is required for the invasion* Correspondence: konkel@vetmed.wsu.edu
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distribution, and reproduction in any mediumof host cells and for the secretion of the inflammatory
chemokine interleukin-8 from host cells. We also show
that the newly identified virulence protein CiaD is
required for the development of disease. The fact that
CiaD is required of the development of disease provides
a significant advancement in the understanding of C.
jejuni pathogenesis.
Background
Campylobacter jejuni is a leading cause of gastroenteritis
worldwide, causing ~1.4 to 2.3 million cases each year in
the United States [1,2]. A serious complication of C.
jejuni infection is the development of Guillain–Barré
syndrome (GBS), an autoimmune disease affecting the
peripheral nervous system [3]. The ability of C. jejuni totral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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requiring cell adherence, invasion, and intracellular survival
[4-10]. Key to host cell invasion and survival is the synthe-
sis of the Campylobacter invasion antigens (Cia) [11]. Cia
proteins are exported from the bacterium’s flagellar Type
III Secretion System (T3SS) and are delivered to the host
cell to promote maximal cell invasion [12].
Only three (CiaB, CiaC, and CiaI) of ~18 Cia proteins
have been identified to date [4,13,14]. While the precise
functions of these proteins are not known, in vivo studies
suggest that they contribute to disease. More specifically,
inoculation of piglets with a C. jejuni wild-type strain
and ciaB mutant results in different clinical signs. Piglets
infected with C. jejuni develop diarrhea within 24 hours,
and exhibit severe histological lesions, including shorten-
ing of the villi and production of an exudate in the lumen.
In contrast, piglets inoculated with a C. jejuni ciaB-knock-
out mutant do not develop diarrhea until 3 days post-
infection and exhibit only minor histological lesions [14].
Introducing a wild-type copy of the ciaB gene into the C.
jejuni ciaB mutant restored the isolate’s virulence [15].
Additional work is needed to identify and characterize the
Cia proteins to gain a better understanding of C. jejuni
pathogenesis.
C. jejuni invades the cells lining the gastrointestinal
tract and induces a potent inflammatory response char-
acterized by the secretion of interleukin-8 (IL-8). However,
little is known about the mechanism underlying the
induction of IL-8 secretion by C. jejuni. Bacterial factors,
such as the flagellum and CpG dinucleotide, are typical
immune stimulators [16]. However, Toll-like receptor 5
(TLR5) is not stimulated by the C. jejuni flagellum [17,18].
Similarly, TLR9, which recognizes CpG dinucleotides,
is not efficiently stimulated by C. jejuni [16]. While C.
jejuni is clearly stimulating a proinflammatory response,
the mechanism of immune activation is not completely
understood.
Researchers have found that the NF-κB pathway is
activated by C. jejuni. The NF-κB pathway is activated by
JlpA, CdtABC, and peptidoglycan (intracellular NOD-1
receptors) [19-21]. While both the NF-κB and AP-1 tran-
scriptional activators are required for expression of the
gene encoding IL-8, also known as huCXCL8 [22], the
mechanism of activation of AP-1 by C. jejuni is not
known. In addition to their role in cell growth and
differentiation, Erk 1/2 and p38 serve as important acti-
vators of the immune response in non-phagocytic cells
through the activation of AP-1. Several labs have reported
that Erk 1/2 and p38 signaling pathways are activated
by C. jejuni, and that the activation of these pathways is
dependent on bacterial de novo protein synthesis and a
functional flagellum [18,23,24]. The C. jejuni factors
necessary for Erk 1/2 and p38 mediated IL-8 secretion
are not known.We hypothesized that C. jejuni delivers one or more
of the Cia proteins to host cells where they trigger the
induction of IL-8 secretion from host cells. Here we
identify a novel protein (Cj0788), which we termed
Campylobacter invasion antigen D (CiaD), that is secreted
via the flagellar T3SS. CiaD is required for maximal C.
jejuni invasion and IL-8 secretion from human INT 407
epithelial cells. We also show that CiaD is required for the
development of acute disease in vivo. Specifically, the C.
jejuni wild-type strain resulted in disease characterized by
a thickening of the gastrointestinal tract wall, enlarged
ileocecocolic lymph nodes, and bloody lumen contents in
cecum and colon, which was absent in mice infected with
the C. jejuni ciaD mutant. These data are significant, as
this is the first time that a C. jejuni effector protein has
been shown to contribute to the development of disease
in a mouse model.
Results
The flagellum is required for CiaD delivery to host
epithelial cells
Previous work in our lab led to the identification of 42
proteins that contain a putative C. jejuni flagellar T3SS
export signal [4]. We sought to determine if one of these
proteins, Cj0788, designated Campylobacter invasion
antigen D (CiaD), is secreted by C. jejuni. We tested if
CiaD is secreted from a C. jejuni wild-type strain and ciaD
mutant harboring a plasmid encoding CiaD fused to the
adenylate cyclase domain (ACD) of the CyaA protein from
Bordetella pertussis. The CiaD-ACD fusion protein was
secreted from the C. jejuni wild-type strain and a ciaD
mutant but not the flgBC flagellar mutant, as judged by
immunoblot analysis using an ACD specific antibody
(Figure 1A and Additional file 1: Figure S1A). To determine
if CiaD is required for Cia secretion, we tested if a second
Cia protein (CiaC) could be exported from the ciaD mutant
transformed with a construct harboring CiaC-ACD. In
addition, the ciaD mutant was transformed with a
construct harboring MetK-ACD (a known cytosolic
protein), as a negative control. In contrast to MetK,
the CiaC effector protein was secreted from the ciaD
mutant (Additional file 1: Figure S1A). These assays
show that CiaD is secreted from a C. jejuni wild-type
strain and is not required for the secretion of other
Cia proteins.
To determine if CiaD is delivered to the cytosol of
human epithelial cells, INT 407 human intestinal cells
were infected with C. jejuni transformed with the CiaD-
ACD construct and host cell cAMP levels were measured
via ELISA as described previously [12]. The C. jejuni
wild-type strain transformed with the CiaC-ACD and
MetK-ACD constructs were included as positive and
negative controls, respectively. All of the fusion proteins
were synthesized in the transformed C. jejuni isolates
Figure 1 CiaD is delivered to the cytosol of human epithelial cells. (A) CiaD is secreted from C. jejuni. A C. jejuni wild-type strain transformed
with the pRY111 vector harboring CiaD fused to the adenylate cyclase domain (CiaD-ACD, + designation) was analyzed by immunoblot analysis. CysM
is a cytoplasmic protein (O-acetylserine sulfhydrylase B) involved in cysteine biosynthesis (Mr = 32.4 kDa). Also included was a C. jejuni wild-type strain
without the pRY111 shuttle vector as a negative control (− designation) and a C. jejuni flgBC mutant expressing CiaD-ACD and a pRY111 shuttle vector.
(B) CiaD is delivered to host cells. A C. jejuni wild-type strain, ciaD mutant, and flgBC mutant were transformed with pRY111 vector harboring the
ciaD-ACD, ciaC-ACD, and metK-ACD inserts. C. jejuni harboring the metK-ACD vector was used as a negative control. The CiaC-ACD, a known delivered
protein, was included as a positive control. The delivery of the CiaD-ACD, CiaC-ACD, and MetK-ACD fusion proteins to the cytosol of human INT 407
cells was determined using the ACD delivery assay described in Methods. The asterisk indicates that the amount of cAMP produced in the wild-type
strain was significantly greater than the value obtained from the flgBC mutant, as judged by one-way ANOVA followed by post-hoc Tukey’s analysis
(P < 0.05). Each error bar represents ± the standard error of the mean (SEM) of N = 9 samples from 3 independent experiments.
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the negative control, a significant increase (P < 0.05) in the
level of cAMP was observed in cells inoculated with the C.
jejuni CiaD-ACD strain (Figure 1B). The delivery of CiaD
was found to be dependent on a functional flagellum,
as infection of INT 407 cells with a C. jejuni flgBC mu-
tant (secretion negative control) transformed with the
CiaD-ACD construct resulted in a significant decrease in
cAMP detected as compared to the C. jejuni wild-type
strain (Figure 1B). We utilized the Cia delivery assay to
determine if the ciaD mutant could deliver CiaC to a
host cell. Again, in contrast to MetK, the CiaC effector
protein was delivered from the ciaD mutant to host
cells, as judged by a significant increase in cAMP versus
the controls.CiaD induces the secretion of IL-8 from epithelial cells
An effector protein is defined as a protein delivered
from a pathogen to a host cell that ultimately functions
to alter host cell behavior. Based on the finding that
CiaD is delivered to host cells, we postulated that CiaD
acts as an effector protein. In-silico analysis was used to
look for eukaryotic domains in CiaD. The web-based
program Eukaryotic Linear Motif (ELM) revealed that
CiaD contained a Mitogen-activated protein kinase docking(MKD) motif (probability score = 0.0043) and a proline-
directed phosphorylation ((S/T)P) motif (probability
score = 0.0154) (Figure 2A) [25,26]. In addition, the
Phyre2 protein folding prediction software [27] revealed
that CiaD contains a putative nucleotidyltransferase
folding domain (52.6% confidence) (not shown). Nucleo-
tidyltransferase domains are commonly found in bacterial
effector proteins involved in adenylylation of RhoGTPase
leading to actin remodeling [28]. The presence of these
eukaryotic domains raised the possibility that CiaD might
alter host cell behavior.
Investigators have reported that C. jejuni de novo
protein synthesis is required for maximal secretion of
IL-8 from host cells [18,29]. Consistent with these reports,
we found that incubation of C. jejuni with chloram-
phenicol (a protein synthesis inhibitor) for 30 min prior
to inoculation of human INT 407 cells reduced the
amount of IL-8 secreted from the host cells as well as
C. jejuni invasion (Additional file 2: Figure S2A and
S2B). Noteworthy is that INT 407 cells are responsive
to innate immune signaling molecules that engage
TLR4 and TLR2 [30]. Previous work has also indicated
that the genes encoding the Cia proteins are induced
when C. jejuni are cultured with epithelial cells [11].
Taken together, these findings raised the possibility that
a Cia protein was required for IL-8 induction. Based on
Figure 2 CiaD is required for the maximal secretion of interleukin-8 from host cells. A) Schematic representation of the CiaD Mitogen-
activated protein kinase docking (MKD) motif residues 137–147 and the proline-directed phosphorylation site ((S/T)P) motif residue 54. (B) CiaD is
required for the maximal secretion of IL-8 by INT 407 cells. The flgBC flagellar mutant was included as a negative control. The values obtained
from uninfected cells were subtracted from all other values. The asterisks indicate a significant reduction in the amount of IL-8 detected in the
supernatants compared to the value obtained using the C. jejuni wild-type strain, using a one-way ANOVA followed by post-hoc Tukey’s analysis
(P < 0.05). Error bars represent ± SEM of N = 12 samples from 3 independent experiments. (C) CiaD is secreted from a C. jejuni ciaD mutant
transformed with pRY111 vector harboring the CiaD-FLAG-tagged protein. Blots were probed with FLAG and CysM antibodies. Also included was
a C. jejuni ciaD mutant without the pRY111 shuttle vector (−) as a negative control. (D) The C. jejuni ciaD mutant is motile. Motility assays were
performed as outlined in Methods. (E) Deletion of ciaD does not have an effect on C. jejuni binding to host cells at 30 min post-infection.
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between IL-8 induction and MAP kinase signaling, we
measured the IL-8 pro-inflammatory chemokine in the
supernatants collected from INT 407 cells inoculated
with the C. jejuni wild-type strain and ciaD mutant.
The C. jejuni flgBC mutant was included as a negative
control; this mutant binds to the cells at levels similar
to that of a C. jejuni wild-type strain but is deficient in Cia
protein secretion and delivery (not shown). A significant
decrease (P < 0.01) in secreted IL-8 was observed in cells
inoculated with the C. jejuni ciaD and flgBC mutants
when compared to a C. jejuni wild-type strain (Figure 2B).
Additionally, IL-8 secretion from host cells was not alteredby removal of non-adherent bacteria by washing or in the
presence of non-adherent bacteria (not shown).
Several additional findings indicate that CiaD is, in
part, responsible for inducing IL-8 secretion from host
cells. First, insertion of a wild-type copy of the ciaD gene
driven by the constitutive promoter hupB into the ciaD
mutant in trans (complemented strain) resulted in an
isolate that displayed an IL-8 secretion phenotype indis-
tinguishable from that of the wild-type strain (Figure 2B).
Second, ectopic expression of a gene that encodes
CiaD-EGFP in host INT 407 cells resulted in a moderate
increase in IL-8 secretion as compared to ectopic
expression of EGFP only (Additional file 3: Figure S3).
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from the ciaD complemented isolate, as judged by
immunoblot analysis (Figure 2C); b) the C. jejuni ciaD
mutant and ciaD complemented isolate are both motile,
as judged by motility assays, indicating a functional
flagellum (Figure 2D); and c) the C. jejuni wild-type
strain, ciaD mutant, and ciaD complemented isolate
bound to INT 407 cells with equal efficiency, as
judged by a cell binding assay (Figure 2E). Moreover,
no difference was observed in the binding of all of the
isolates to the host cells over an eight-hour period
(not shown). In separate assays, we found that the
inoculation of INT 407 cells with an isolate that
contained a knockout in Cj0789, which is the gene
immediately downstream of ciaD, resulted in a similar
level of secreted IL-8 as that of the wild-type strain
(Additional file 4: Figure S4). Consistent with the pro-
posal that the delivery of CiaD to host cells requires
bacteria-host cell contact, the addition of supernatants
containing the Cia proteins to INT 407 cells did not
induce IL-8 secretion (not shown). Based on these
data, we concluded that CiaD is an effector protein
that is involved in the induction of IL-8 secretion.CiaD is required for cell invasion
We performed experiments to determine if there is a
possible link between IL-8 induction and C. jejuni
invasion of host cells. The ability of the C. jejuni ciaD
mutant to invade INT 407 cells was determined using the
gentamicin-protection assay. The C. jejuni ciaC mutant
was included as a control, as this mutant displays a
significant reduction in cell invasion compared to a
wild-type strain of C. jejuni. Both the C. jejuni ciaD and
ciaC mutants exhibited a reduction in cell invasion when
compared to a wild-type strain (Figure 3A). To determine
if cell invasion is required to induce IL-8 secretion from a
host cell, INT 407 cells were inoculated with the C. jejuni
ciaD and ciaC mutants and the amount of IL-8 secreted
into the supernatants was determined. Consistent with
our previous findings, CiaD was required to induce
maximal IL-8 secretion (Figure 2B). We also found that
the ciaC mutant induced levels of IL-8 secretion indistin-
guishable from the C. jejuni wild-type strain (Figure 3B).
This finding suggested that invasion and IL-8 secretion
are not directly linked.
To address the role of MAP kinase signaling in C. jejuni
induction of IL-8 secretion and host cell invasion, assays
were performed in the presence of cellular inhibitors to
Erk 1/2 (PD98059) and p38 (SB202190). Inhibition of Erk
1/2 and p38 resulted in a significant reduction (P < 0.01)
in the number of C. jejuni internalized (Figure 3C) and the
amount of secreted IL-8 (Figure 3D). Consistent with
these findings, we found that the amount of IL-8 secretedby the host cells inoculated with the CiaD mutant was
reduced significantly when the activation of Erk 1/2
and p38 were inhibited (Additional file 5: Figure S5).
Specifically, inhibition of Erk 1/2 results in a 70%
reduction in the amount of IL-8 secreted from host
cells infected with a C. jejuni wild-type strain,
similarly inhibition of Erk 1/2 resulted also in a reduc-
tion in IL-8 secreted from host cells that were infected
with the C. jejuni ciaD mutant. These results are con-
sistent with the fact that the C. jejuni ciaD mutant ac-
tivates Erk 1/2 to a level that is slightly above that of
cells only. Moreover, the addition of exogenous IL-8
to Caco-2 cells, an intestinal cell line that is responsive
to IL-8 because of the presence of the CXCR1 and
CXCR2 receptors, did not restore the invasiveness of
the C. jejuni ciaD mutant to that of a C. jejuni wild-type
strain (Additional file 6: Figure S6). This finding suggests
that the invasion phenotype of the ciaD mutant is due to a
lack in the initiation of cellular signaling events specific to
invasion, and not from the failure to induce the secretion
of IL-8 from host cells. We also confirmed that Caco-2
cells are responsive to IL-8, using immunoblot analysis
to quantify phospho-Akt; Akt is a downstream target of
the CXCR1/2 receptors and is activated by IL-8 [31]
(Additional file 6: Figure S6B). Together, these experiments
revealed that C. jejuni must activate components of the
MAP kinase signaling pathway for both cellular invasion
and the secretion of IL-8, and that CiaD contributes to this
activation.
CiaD activates of the MAP kinase signaling pathway
Based on the presence of the Mitogen-activated protein
kinase docking (MKD) motif in CiaD, experiments were
performed to determine if C. jejuni activated the MAP
kinase signaling pathway in a CiaD dependent manner.
Prior to performing these experiments, we determined
that the C. jejuni wild-type strain induces significantly
more IL-8 than the ciaD mutant at 4 hr post-inoculation
of INT 407 cells (Figure 4A). Based on the kinetics of
IL-8 secretion, we performed experiments to identify the
cellular signaling pathways that are activated by C. jejuni
at 3 hr post inoculation. The use of a MAP kinase
phosphor-array screen revealed that the C. jejuni ciaD
mutant did not activate Erk 1/2 and p38 to the same
extent as inoculation of the INT 407 cells with the wild-
type strain (Additional file 7: Figure S7). These results
were confirmed by immunoblot analysis (Figure 4B and
Figure 4C). The partial activation (above cells only) of
Erk 1/2 by the ciaD mutant is consistent with the fact
that Erk 1/2 is also partially activated in response to host
cell binding mediated by FlpA [32]. In contrast to the
C. jejuni ciaD and flgBC (Cia protein secretion-negative)
mutants, the C. jejuni wild-type strain and ciaD mutant
harboring a wild-type copy of the ciaD gene (complemented
Figure 3 IL-8 secretion from INT 407 cells is not invasion dependent, but MAPK activation is required for host cells invasion by
C. jejuni. (A) A C. jejuni ciaD mutant is deficient in maximal invasion of INT 407 cells. The C. jejuni ciaC mutant was included as an invasion
deficient control. (B) IL-8 secretion does not require bacterial invasion. INT 407 cells were inoculated with various C. jejuni isolates, incubated for
24 hr, and IL-8 quantified using an IL-8 ELISA as described in Methods. The C. jejuni flgBC flagellar mutant (Cia secretion negative) and C. jejuni
ciaC mutant (CiaC secretion negative and invasion deficient) were included as negative controls. (C) MAP kinase activation is required for C. jejuni
invasion. Inhibitors to Erk 1/2 (PD98059) and p38 (SB 202190) were added to INT 407 cells for 30 min prior to the addition of a C. jejuni wild-type
strain. (D) MAP kinase activation is required for IL-8 secretion. Inhibitors of Erk 1/2 and p38 were added to INT 407 cells for 30 min prior to
inoculation with a C. jejuni wild-type strain. The values obtained from uninfected cells were subtracted from all other values. The asterisks indicate
a significant reduction compared to the value obtained for the C. jejuni wild-type strain, according to one-way ANOVA followed by post-hoc
Tukey’s analysis (P < 0.05). Error bars represent ± SEM of N = 12 samples from 3 independent experiments.
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judged by an increase in band intensity of the phos-
phorylated form of the protein. Even though the C.
jejuni wild-type strain, ciaD mutant, and complemented
ciaD isolate resulted in greater activation of NF-κB
(p65 subunit phospho-S536) compared to the flgBC
mutant, significant differences were not observed in
the amount of NF-κB activation between the isolates
(Figure 4B and 4C). This finding suggested that a protein
or other bacterial component other than CiaD is re-
sponsible for the activation of NF-κB. Taken together,
our results indicate that CiaD participates in the activation
of the MAP kinase signaling molecules Erk 1/2 and p38.The MAP Kinase docking motif of CiaD is required for IL-8
secretion and host cell invasion
Mutational analysis was used to determine whether the
putative eukaryotic domains of CiaD are functional. Two
C. jejuni ciaD mutants were generated; the MAP kinase
docking motif was deleted (ΔMKD) in one mutant and
the proline-directed phosphorylation motif was changed
to an alanine (ΔS/T)P) in the other mutant (Figure 5A).
Immunoblot analysis revealed that both CiaD recom-
binant proteins were synthesized in the ciaD mutant
(Additional file 8: Figure S8A). Importantly, all of the
isolates were motile (Additional file 8: Figure S8B). Ex-
periments were then performed to evaluate the ability
Figure 4 CiaD is required for activation of the MAP kinase signaling cascade. (A) The amount of IL-8 in supernatants is significantly increased
4 hr post infection in the C. jejuni wild-type strain when compared to the ciaD mutant. (B) Maximal activation of p38 and Erk 1/2 requires CiaD, as
judged by immunoblots. Immunoblots were probed with phospho-specific antibodies to Erk 1/2 (Mr = 42 and 44 kDa), p38 (Mr = 38 kDa), and NF-κB
p65 subunit phospho-S536 (Mr = 65 kDa). All blots were stripped and re-probed with an anti-tubulin (Mr = 52 kDa) antibody. (C) Maximal activation of
p38 and Erk 1/2 requires CiaD. Densitometry was performed on the immunoblots shown in Panel B. The value obtained for cells only was subtracted
from all other values. The asterisks indicate a significant difference in values compared to the controls, as judged by one-way ANOVA followed by
post-hoc Tukey’s analysis (P < 0.05). Error bars represent ± SEM of N = 6 samples from 6 independent experiments.
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to induce IL-8 secretion and to invade human INT 407
epithelial cells. The CiaD ΔMKD mutant was unable to
induce secretion of IL-8 from host cells, and was equally
impaired in its ability to invade host cells (Figure 5B
and C). In contrast, the CiaD (ΔS/T)P mutant induced
the secretion of IL-8 and invaded host cells to a level
that was indistinguishable from the C. jejuni wild-type
strain (Figure 5B and C). These results indicate that the
MKD motif of CiaD is required to modify a host cell
signaling pathway(s), and that the interaction of CiaD
with a host protein leads to IL-8 secretion and cell
invasion.
The phenotype of the ciaD mutant is the same in C. jejuni
F38011 and 11168 strains
Prior to assessing whether ciaD contributes to the devel-
opment of acute disease in vivo, it was first necessary toregenerate the ciaD mutant in the C. jejuni 11168 mouse
adapted strain and confirm if the mutants behaved in a
similar fashion as the C. jejuni F38011 ciaD mutant. More
specifically, four isolates were used in these experiments:
a) the C. jejuni 11168 wild-type strain; b) the C. jejuni
11168 ciaD mutant; c) the ciaD mutant that synthesizes
a CiaD wild-type protein; and d) the ciaD mutant that
synthesizes the CiaD ΔMKD recombinant protein. We
did not regenerate a ciaD mutant that synthesizes the
CiaD Δ(S/T)P mutant protein, as the C. jejuni F38011
isolate that synthesizes this recombinant protein did not
yield a unique phenotype. The CiaD protein was readily
detected in the C. jejuni 11168 ciaD mutant transformed
with the vectors that encode for the CiaD wild-type
protein and CiaD ΔMKD-site protein (Additional file 8:
Figure S8A). All of the isolates tested were motile
(Additional file 8: Figure S8B). We then measured the
amount of IL-8 and MIP-2 (a homologue of IL-8 in
Figure 5 The MKD site of CiaD is necessary for cellular invasion and IL-8 secretion. (A) Schematic representation of the CiaD wild-type
protein, the CiaD MAP kinase docking motif (ΔMKD site) mutant protein, and CiaD proline directed-phosphorylation site (Δ(S/T)P) mutant protein.
(B) The MKD site of CiaD is required for C. jejuni to induce maximal IL-8 secretion from INT 407 cells. The value obtained from cells only was
subtracted from all other values. (C) The MKD site of CiaD is required for maximal C. jejuni invasion of INT 407 cells. The asterisks indicate a
significant difference compared to the C. jejuni wild-type strain, as judged by one-way ANOVA followed by post-hoc Tukey’s analysis (P < 0.05).
Error bars represent ± SEM of N = 12 samples from 3 independent experiments.
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CT-26 cells inoculated with the various C. jejuni strains,
respectively. The results obtained with the C. jejuni 11168
isolates in INT 407 cells mirrored those obtained with the
C. jejuni F38011 strain in INT 407 cells for IL-8 secretion
and cell invasion (Figure 6A and B). Similarly, we observed
that the ciaD mutant and ciaD mutant that synthesize
the CiaD ΔMKD-site recombinant protein were deficient
in the ability to induce MIP-2 secretion and invade CT-
26 cells (Figure 6C and D). These data indicate that the
phenotypes of the 11168 mouse adapted isolates are
indistinguishable to that of the C. jejuni F38011 isolates,
and that CiaD is required for MIP-2 secretion and cell
invasion. Given these findings, we then performed in vivo
experiments to determine the contribution of CiaD to
campylobacteriosis.
CiaD is required for the development of disease
C57BL/6 IL-10−/− mice were infected with a C. jejuni
11168 wild-type strain, a ciaD mutant, and a ciaD
complemented isolate to assess the contribution of CiaD
to the development of disease. Mice sham-inoculatedwith tryptic soya broth (TSB) were included as a negative
control. We found that mice infected with the C. jejuni
ciaD mutant exhibited less severe disease when compared
to the C. jejuni wild-type strain, as judged by mouse
survival (Additional file 9: Figure S9A), gross pathology
(Figure 7A), histopathology (Figure 7B and C) and
plasma IgG2b anti-C. jejuni antibody levels (Additional
file 10: Figure S10). C. jejuni was only recovered at necropsy
(either 35 or 36 days after inoculation) from mice inoc-
ulated with the wild-type strain (Additional file 9: Figure
S9B); however, the fact that IL-10−/− mice are unable to
down-regulate inflammatory processes once they are
initiated makes it possible to detect disease after pathogen
clearance. Importantly, the C. jejuni ciaD mutant express-
ing a wild-type copy of ciaD produced more severe clinical
signs of disease in some mice compared to the ciaD
mutant (Figure 7A-C). The C. jejuni ciaD mutant produced
no GI lesions, comparable to the TSB controls (Figure 7C,
panels 1 and 3) and in contrast to the 11168 wild-type
strain that produced severe end stage typhlocolitis with
neutrophilic exudates, increased crypt height, crypt
abscesses, mononuclear cell infiltration and massive
Figure 6 CiaD function is conserved between strains of C. jejuni and different cell types. (A) The MAP kinase docking motif of CiaD is
required for IL-8 secretion from human INT 407 cells. Cells only were subtracted from all shown values. (B) The MAP kinase docking motif of CiaD
is required for maximal invasion of human INT 407 cells. (C) The MAP kinase docking motif of CiaD is required for MIP-2 secretion from murine
CT-26 cells. MIP-2 concentrations were quantified using an MIP-2 ELISA as described in Methods. Cells only were subtracted from all shown
values. (D) The MAP kinase docking motif of CiaD is required for maximal invasion of murine CT-26 cells. The asterisks indicate a significant
difference in the value versus that of the C. jejuni wild-type strain, as judged by one-way ANOVA followed by post-hoc Tukey’s analysis (P < 0.05).
Error bars represent ± SEM of N = 12 samples from 3 independent experiments.
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the ciaD mutant expressing a wild-type copy of ciaD
produced a marked increase in gross pathology (i.e.,
thickening of GI tract wall and/or enlarged ileocecocolic
lymph node) and histopathology (i.e., increased crypt
height, goblet cell hyperplasia, and mononuclear cell infil-
tration) (Figure 7C, panel 4). Application of an established
histopathologic scoring system to ileocecocolic sections
from mice in all groups confirmed these observations
(Figure 7B). Specifically, the ciaD mutant expressing a
wild-type copy of CiaD exhibited a significant increase
in gross pathology (i.e., thickening of GI tract wall and/
or enlarged ileocecocolic lymph node). Theoretically,
the ciaD complemented isolated would have achieved
the same level of histopathology as the wild-type if ithad been allowed to go longer. These results suggest
that CiaD is contributing to the development of disease
in vivo, but that colonization of IL-10−/− mice is a
multi-factorial process. Together, these data indicate
that CiaD is necessary for the development of disease
in the IL-10−/− mouse model of campylobacteriosis.
Discussion
In this study we identified and characterized a novel
C. jejuni effector protein that is secreted and delivered
to host cells via the flagellar T3SS. We found that
CiaD is delivered to the cytosol of human INT 407
epithelial cells via a flagellar T3SS, where it is involved in
maximal activation of the MAP kinase signaling pathways
Erk 1/2 and p38. Interestingly, CiaD contains a MKD that
Figure 7 CiaD is required for the development of severe disease. (A) Gross pathology of IL-10−/− mice infected with C. jejuni. Significant
differences in gross pathology were observed between the C. jejuni wild-type strain and the ciaD mutant. The C. jejuni ciaD complemented isolate
partially restored the gross pathology to levels intermediate between the C. jejuni wild-type strain and ciaD mutant. (B) Ileocecocolic
histopathologic lesion scores of all mice in the in vivo oral challenge study. Lesion scores for the ciaD mutant group and the C. jejuni wild-type
group were significantly different, based on nonparametric Kruskal Wallis one-way ANOVA followed by the Mann–Whitney test for pairwise
comparisons and the Holm-Šidák procedure for correction for multiple comparisons. Lesion scores in the ciaD complemented group showed that
3/13 (23%) of mice had restoration of the inflammatory phenotype. One mouse in the trypticase soy broth (TSB) treated group had spontaneous
colitis. (C) Representative histopathology of ileocecocolic junctions. Bars represent 100 μm. Treatment groups were as follows: (1) mouse sham
inoculated with trypticase soy broth, (2) mouse infected with the C. jejuni wild-type strain 11168, (3) mouse infected with the ciaD mutant, and
(4) mouse infected with the ciaD complemented isolate. Note that the knockout of ciaD prevented tissue inflammation (panel 3) with tissues
appearing similar to the TSB controls (panel 1); brackets in panels 1 and 3 show the normal crypt height. Mice receiving the C. jejuni wild-type
strain (panel 2) had severe end stage typhlocolitis with significant increases in the crypt height of the lamina propria (upper bracket) and
submucosa due to edema (lower bracket). Mononuclear cell infiltrates (dark purple cells) can be seen throughout the tissue. Complementation
with ciaD restored the phenotype to that of severe typhlocolitis in the mouse shown in panel 4.
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pathways, leading to the secretion of IL-8 and invasion
of host cells. MAP kinases are activated by the phos-
phorylation of their tyrosine and threonine residues by
their specific MAP kinase kinase (MAPKK). The phos-
phorylation of MAP kinases are facilitated by a specific
MKD motif, which allows the proper interaction to occur
without crosstalk to inappropriate signaling molecules.
We also report that CiaD is required for the development
of acute disease and colon lesions.
MKD’s have been identified in several bacterial effector
proteins, including SpvC, OspF, and VP1680 from
Salmonella enterica, Shigella spp. and V. parahaemolyticus,
respectively [33-36]. The SpvC and OspF MKD canonical
(K/R)1–2-(X)2–6-OA-X-OB sequence [37] are located
near the N-terminus in a disordered region. Similarly,
both proteins have been shown to interact with Erk 1/2 tofacilitate the irreversible dephosphorylation of threonine
residues crucial for Erk 1/2 activation [38]. However,
the MKD is located centrally within a region of low-
complexity in the V. parahaemolyticus effector VP1680.
VP1680 is necessary for the activation of the p38 and
Erk 1/2 signaling pathways [36]. Bioinformatics analysis
of CiaD shows that the MKD is near the C-terminus in
an area of low-complexity and is required for maximal
activation of Erk 1/2 and p38. These data also suggest
that there are two distinct classes of MKD containing
effector proteins. One class inhibits the activation of
these pathways (i.e., SpvC and OspF) and the other
class stimulates the activation of the MAP kinases (i.e.,
VP1680 and CiaD). The CiaD (ΔS/T)P mutant induced
the secretion of IL-8 and invaded host cells to a level
that was indistinguishable from a C. jejuni wild-type
strain. This finding suggests that CiaD does not need to
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the possibility CiaD is phosphorylated at another site.
Inhibition of either Erk 1/2 or p38 has been reported
to lead to a significant decrease in the amount of C.
jejuni internalized into host cells [23]. However, others
have shown that these pathways do not affect bacterial
invasion [18]. Our results support the findings that Erk
1/2 and p38 are necessary for maximal invasion by C.
jejuni. While Erk 1/2 and p38 have also been shown to
be necessary for invasion of Shigella, Chlamydia, and
Salmonella spp. [39-41], the molecular mechanism by
which Erk 1/2 and p38 promote bacterial invasion of
intestinal cells is not known. It may be that the activation
of Erk 1/2 and p38 alter gene transcription and the syn-
thesis of proteins necessary for bacterial uptake or that
Erk 1/2 and p38 activate other cellular proteins involved
in bacterial invasion.
Acute inflammation caused by C. jejuni or other invasive
enteric pathogens, such as Shigella spp. and Salmonella
enterica serotype Typhimurium (S. Typhimurium), is asso-
ciated with extensive epithelial injury and necrosis of
the colon and the terminal ileum, with neutrophils being
responsible for the tissue damage accompanying exudative
inflammation. These processes all contribute to intestinal
fluid accumulation and exudative diarrhea often with
hemorrhage. Similarly, the inflammatory response is
associated with changes in the gut microbiota, including
an increased abundance of bacteria belonging to the
family Enterobacteriaceae [42]. We show that the de-
velopment of disease requires CiaD. The introduction
of the wild-type copy of ciaD into the ciaD mutant
resulted in greater gross- and histopathologic lesions
than infection with the ciaD mutant, but somewhat
less changes than the C. jejuni wild-type strain. One
possible reason for this intermediate phenotype is that
the expression of the wild-type copy of ciaD in the
mutant may be altered. The partial restoration in virulence
observed with the C. jejuni ciaD complemented isolate
is consistent with the results of complementation ex-
periments performed by others using in vitro challenge
studies [14,43]. Noteworthy is that this is the first time
that a C. jejuni effector protein has been found to be
required for the development of disease in a mouse
model. This is also in agreement with our previous
results indicating that the Cia proteins contribute to the
development of disease in piglets [14]. More specifically,
infection of piglets with a ciaB mutant exhibited less
severe disease as compared to a C. jejuni wild-type strain,
as judged by clinical presentation and histopathology [14].
We discovered CiaD is required for the maximal inva-
sion of human epithelial cells, induction of the inflamma-
tory response, and the activation of the cellular signaling
components Erk 1/2 and p38. We demonstrate that CiaD
is necessary for the development of disease and coloninflammatory lesions in vivo using the IL-10 KO mouse
model for campylobacteriosis. In addition, we observed a
plasma IgG2b anti-C. jejuni antibody response in mice
infected with the C. jejuni wild-type strain and comple-
mented ciaD isolate, suggesting that C. jejuni stimulates a
general proinflammatory response in IL-10−/− mice. We
believe that CiaD is, in part, responsible for the generation
of plasma IgG2b anti-C. jejuni antibody response, as this
response was not observed in mice inoculated with the
ciaD mutant (Additional file 10: Figure S10). This finding
is consistent with the fact that: 1) T-cell derived IL-10 is
an inhibitor of the Th1 immune response, so an absence
of IL-10 promotes a robust Th1 directed antibody re-
sponse (predominantly IgG2b) [44]; and 2) The C. jejuni
wild-type strain and complemented ciaD isolate are more
invasive than the ciaD mutant. Noteworthy is that the
Th1 “cell mediated” immune response is observed with
invasive pathogens, including C. jejuni [44-47]. In con-
clusion, this is the first time that a C. jejuni effector
protein has been shown to contribute to the development
of acute disease. Future work will be directed towards the
identification of a host cell-binding partner of CiaD, and
to understand the role of Erk 1/2 and p38 in the larger
scope of bacterial invasion.
Methods
Bacterial strains, tissues culture types, and plasmids
Campylobacter jejuni strains for in vitro experiments were
cultured on Muller-Hinton agar plates supplemented with
bovine citrated 5% (v/v) blood (MHB). Cultures for mouse
inoculation studies were grown on trypticase soy agar
containing 5% sheep’s blood. When appropriate, chlor-
amphenicol (8 μg/ml) and tetracycline (2 μg/ml) were
added to the media. Cultures were grown at 37°C in
microaerobic conditions (5% O2, 10% CO2, and 85% N2).
Cell lines used in this study were obtained from the
American Type Tissue Culture Collection. INT 407
(ATCC CCL 6) and Caco-2 (ATCC HTB-37) cells were
cultured in Minimal Essential Medium (MEM)
supplemented with 10 mM sodium pyruvate, 20 mM
glutamine, and 10% (v/v) fetal bovine serum (FBS). CT-
26 (ATCC CRL-2638) cells were cultured in RPMI
supplemented with 10% (v/v) fetal bovine serum (FBS).
Plasmids and bacterial isolates used in this study are de-
scribed in the Supplemental Methods (Additional file 1)
and Additional file 11: Table S1. Primers used in
this study are described in Supplemental Methods
(Additional file 1) and Additional file 12: Table S2.
Secretion assay
Secretion assays were performed as previously described
[12]. Briefly, overnight cultures of C. jejuni grown in 0.05%
DOC MH broth were harvested and a bacterial suspension
was added to 3 mL MEM +1% FBS for a final OD540 of
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under microaerobic conditions. Following incubation,
supernatants were concentrated 100-fold by precipita-
tion with 4 volumes of ice-cold 1 mM HCl-acetone.
Samples were separated by SDS-PAGE, transferred to
polyvinylidene fluoride (PVDF) membranes, and blots
were probed with antibodies against FLAG, CysM, and
the ACD of cyaA.
Cia protein delivery assays
Secretion assays were performed as previously described
[12]. C. jejuni overnight cultures grown in 0.05% DOC
MH broth were harvested, and the bacterial suspension
was added to MEM+ 1% FBS for a final OD540 of 0.015/
ml. INT 407 cells were washed once with PBS and 1 mL
of a 0.015 OD540 mixture was added to each well of the
24-well tissue culture tray. The trays were centrifuged
for 5 min at 800 × g and incubated for 30 min at 37°C.
The media in the wells were removed and the wells were
washed 3 times with PBS followed by the addition of 95°C
0.1 M HCl. Each tray was boiled for 15 min by placing it
on a platform directly above boiling water. Lysates were
collected and transferred to a clean centrifuge tube. cAMP
levels were assessed using the Direct Cyclic AMP Enzyme
Immunoassay Kit (Assay Designs) according to manufac-
turer’s specifications.
Immunoblot analysis, cellular inhibitors, antibodies, and
densitometry analysis
Bacterial whole cell lysates, serum supernatant samples,
and INT 407 cellular lysates were collected and analyzed
by SDS-polyacrylamide gel electrophoresis. The proteins
were transferred to a PVDF membrane and probed with
the indicated antibodies. The antibodies used in this work
are described in the Supplemental Methods (Additional
file 1). Band intensity was quantified using a LAS 4000
mini (GE healthcare) and the Multi Gauge V3.0 (Fujifilm,
Valhalla, NY) software package. Inhibitors were added
to the cells 30 min prior to infection and maintained
thorough the experiment. The Erk 1/2 (PD98059) and the
p38 (SB202190) inhibitors were used at a concentration of
50 M. Cell death was quantified by trypan blue straining.
No significant death was observed with any treatment
conditions. C. jejuni was pretreated with chloramphenicol
(1024 μg/ml) for 30 min prior to infection of host cells
and maintained throughout the experiment. Chloram-
phenicol treatment did not effect bacterial viability. This
concentration of chloramphenicol completely inhibited
bacterial protein synthesis, as judged by 35[S]-methionine
incorporation assays (not shown and [7]).
Ectopic expression
EGFP plasmids were purified using the Qiagen Plasmid
Purification Kit (Qiagen, Valencia, CA) according to themanufacturer’s protocols and normalized to 200 ng/μl.
Purified plasmids where transfected into INT 407 cells
seeded on glass coverslips at a confluencey of 3 × 105.
Transfections where performed using the Qiagen Effectene
Transfection reagent (Qiagen, Valencia, CA), according to
the manufacturer’s specifications.
Invasion and motility assays
Binding and internalization assays [48] and motility assays
[12] were performed as previously described.
IL-8 quantification
Interleukin-8 levels in cellular supernatants were quan-
tified with a commercial ELISA kit (OptEIA Set, Becton
Dickinson, Cowley, Oxford, UK) using the manufacturer’s
protocol. Briefly, cells were inoculated with 3 × 107 bacteria
and centrifuged for 5 min at 800 × g to promote cell con-
tact. After 30 min of incubation, the cells were washed one
time and fresh media was added to each well (containing
inhibitors where indicated). The cells were incubated at
37°C for 24 hr and the media collected. Supernatants
were frozen at −20°C or used immediately.
Bioinformatics
Operon prediction was performed using MicrobesOnline
[49]. Euckaryotic linear motif analysis was performed by
query of the ELM website (http://elm.eu.org, [25]).
Animals
All animal experiments were conducted according to
NIH guidelines under Michigan State University Animal
Use Form approval 06/012-107-00. Two replicate experi-
ments were conducted. A breeding colony of C57BL/6 IL-
10−/− mice (B6.129P2-IL10tm1Cgn/J) was maintained in a
specific-pathogen-free colony at MSU with monitoring for
genotype and colitogenic bacteria as previously described
[44]. For experiments, mice were transferred to the Uni-
versity Research Containment Facility at MSU where they
were individually housed in filter top cages, on sterile food
and water ad libitum.
C. jejuni inoculation of IL-10−/− mice
Mice 8–12 weeks old were infected with ~1 × 1010 cfu C.
jejuni by oral gavage and observed daily for clinical signs
using standardized scoring criteria as previously described
[44]. Mice were humanely euthanized and necropsied
promptly when clinical signs of severe disease developed
or at thirty-five days post-infection. Blood samples were
obtained by cardiac puncture immediately following death
of the mouse. The gastrointestinal (GI) tract was removed
in its entirety and placed on clean absorbent bench paper.
Observations on gross pathological changes were recorded
during necropsy.
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Gross pathology examination in all portions of the GI
tract was performed by trained personnel as previously
described [44]. The following criteria were used for
scoring: no gross pathological changes (None, 0); either
thickening of the GI tract wall or enlarged ileocecocolic
lymph node (ICC or TW, 1); both thickening of GI
tract wall and enlarged ileocecocolic lymph node (ICC
and TW, 2); and bloody lumen contents in cecum or
colon or both (BLC, 3). For histopathology, the ileoce-
cocolic junction was removed and injected with 10%
phosphate buffered formalin (Fisher Scientific, Pittsburgh,
PA, USA), placed in a histological cassette and submerged
in 10% phosphate buffered formalin. After 24 hr, the
cassette was drained and transferred to 60% ethanol.
Tissue processing, paraffin embedment, sectioning, and
hematoxylin and eosin staining were carried out at the
Investigative Histopathology Laboratory, Division of
Human Pathology, Department of Physiology, Michigan
State University. After randomization and coding to
conceal identity, slides were read in a blinded fashion
by a single investigator (LSM) according to a previously
described scoring system [44].
Plasma IgG2b anti-C. jejuni antibody
Plasma IgG2b anti-C. jejuni levels were determined via
ELISA as previously described [44].
Statistical analysis
All data was evaluated using a one-way ANOVA followed
by post-hoc Tukey’s or Dunnet’s analysis of the means,
using Prism 6 (GraphPad Software, La Jolla, CA). Statis-
tical significance was defined by a maximum value of
*P < 0.05 for all in vitro experiments and *P < 0.10 for all
in vivo experiments. All experiments were performed a
minimum of three times to ensure reproducibility. Kaplan
Meier log rank analyses were performed using SigmaStat
3.1 (Systat Software, Port Richmond, CA) to assess the
survival data. Gross pathology was analyzed using
SigmaStat 3.1. The nonparametric Kruskal Wallis one-
way ANOVA was used for gross pathology scoring.
Scores for analysis of gross pathology data were assigned
as follows: no gross pathological changes (None, 0); either
thickening of GI tract wall or enlarged ileocecocolic lymph
node (ICC or TW, 1); thickening of GI tract wall and
enlarged ileocecocolic lymph node (ICC and TW, 2); and
thickening of GI tract wall and enlarged ileocecocolic
lymph node plus bloody lumen contents in cecum or
colon or both (BLC, 3). Kruskal Wallis nonparametric
one-way ANOVA was performed. Mann Whitney pairwise
comparisons with Holm-Sidak correction for multiple
comparisons was performed to evaluate the difference
between the means of the samples, as described previously
[44]. Plasma IgG2b anti-C. jejuni levels were evaluatedwith Kruskal Wallis one-way non-parametric ANOVA,
followed by Mann Whitney pairwise comparisons with
Holm-Sidak correction for multiple comparisons of the
means.Supplemental information
The data sets supporting the results of this article are in-
cluded within the article and its additional files.Additional files
Additional file 1: Figure S1. The C. jejuni ciaD mutant secretes a
known effector protein. (A) The ciaD mutant is Cia secretion competent.
A C. jejuni ciaD mutant was transformed with the pRY111 vector
harboring CiaD, CiaC and MetK fused to the ACD and the isolates were
analyzed by immunoblot analysis. Supernatant and whole cell lysates
were separated by SDS-PAGE, proteins transferred to PVDF membranes,
and blots probed with an ACD antibody and CysM antibody. A C. jejuni
wild-type strain without a plasmid and the MetK-ACD (S-adenosylmethionine
synthetase) protein, which is localized in the bacterial cytoplasm, were
included as negative controls. Molecular mass standards, in kilodaltons (kDa),
are indicated on the left. Arrows indicate the CiaD-ACD and CiaC-ACD
secreted proteins. (B) The C. jejuni CiaC-ACD, CiaD-ACD, and CiaC-ACD fusion
proteins are synthesized in similar levels. The C. jejuni wild-type strain, ciaD,
and a flgBC mutant transformed with the pRY111 vector harboring CiaD, CiaC
and MetK fused to the ACD were analyzed by immunoblot analysis. Protein
levels were quantified by BCA, normalized to ensure equal loading, separated
by SDS-PAGE, transferred to PVDF membranes, and blots probed with an ACD
antibody.
Additional file 2: Figure S2. C. jejuni requires de novo protein synthesis
for bacterial invasion and induction of secretion. (A) Pre-treatment of C.
jejuni with chloramphenicol inhibits INT 407 cell invasion. C. jejuni were
pretreated with chloramphenicol (1024 μg/mL) for 30 min prior to
infection of INT 407 cells. Cell invasion was assessed using a gentamicin-
protection assay as outlined in Supplemental Methods (Additional file 1).
(B) C. jejuni requires de novo protein synthesis for maximal IL-8 secretion.
An IL-8 secretion time course assay was performed by infecting INT 407
cells with a C. jejuni wild-type strain that had been pretreated for 30 min
with chloramphenicol (1024 μg/mL) and harvesting the supernatants at
various times post-infection. IL-8 in the supernatant samples was
quantified by ELISA as described in Methods. Gray bars indicate IL-8
quantities from INT 407 cells infected with an untreated C. jejuni wild-type
strain. The black bars indicate IL-8 quantities from INT 407 cells infected with
a C. jejuni wild-type strain that was pre-treated with chloramphenicol. The
asterisks indicate the time points (4 and 6 hr) at which there are significant
differences in the amount of IL-8 produced compared to the untreated
samples, as judged by one-way ANOVA followed by post-hoc Tukey’s
analysis (P < 0.05). Error bars represent ± SEM.
Additional file 3: Figure S3. Ectopic expression of CiaD in host INT 407
cells induces IL-8 secretions. INT 407 cells were transfected with CiaD-EGFP
and EGFP-only eukaryotic expression vectors. Cells treated with the
transfection reagent Effectene were also included as a vehicle control. IL-8
levels were assessed by ELISA 24 hr following transfection. The asterisks
indicate that the amount of IL-8 produced was significantly increased
compared to the EGFP-only control, as judged by student’s t-test (P < 0.05).
Error bars represent ± SEM.
Additional file 4: Figure S4. Mutation of Cj0789, which is the gene
downstream of ciaD, does not have an effect on IL-8 secretion, indicating
the Cj0788 mutation is not polar. INT 407 cells were infected with C.
jejuni for 24 hr. Following infection, supernatants were collected and IL-8
levels quantified using an IL-8 ELISA. The asterisks indicate that the
amount of IL-8 produced was significantly decreased compared to the C.
jejuni wild-type strains (F38011 and NCTC 11168), as judged by one-way
ANOVA followed by post-hoc Tukey’s analysis (P < 0.05). Error bars
represent ± SEM.
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effect in IL-8 secretion by the C. jejuni ciaD mutant. Inhibitors to Erk 1/2
and p38 were added to INT 407 cells for 30 min prior to the addition of
the C. jejuni ciaD mutant. The C. jejuni wild-type strain was included as a
positive control. The mean value calculated for ‘cells only’ was subtracted
from all other values. The asterisk indicates a significant reduction in the
amount of IL-8 secreted form INT 407 cells infected with the ciaD mutant
in the presence of the Erk 1/2 and p38 inhibitors as compared to the
value obtained for the untreated INT 407 cells infected with the C. jejuni
ciaD mutant, as judged by one-way ANOVA followed by post-hoc Tukey’s
analysis (P < 0.05). Error bars represent ± SEM.
Additional file 6: Figure S6. The pro-inflammatory cytokine IL-8 is not
required for bacterial invasion. (A) Caco-2 cells were infected with C.
jejuni for 30 min followed by the addition of 300 pg/ml of IL-8 to the C.
jejuni ciaD mutant and wild-type strain. The bars represent the mean of
bacterial invasion of the wild-type and the ciaD mutant with the addition
of IL-8 or no treatment. (B) The activation status of Akt was determined
via immunoblot to confirm IL-8 induced signaling. 300 pg/ml of IL-8 was
added to INT 407 cells for 15 min and cellular lysates were prepared.
Blots were probed with phospho-specific antibodies to Akt (Mr = 62 kDa).
All blots were stripped and re-probed with an anti-Akt (Mr = 60 kDa)
antibody. The asterisk indicates a significant decrease compared to the
C. jejuni wild-type strain, as judged by one-way ANOVA followed by
post-hoc Tukey’s analysis (P < 0.05). Error bars represent ± SEM.
Additional file 7: Figure S7. The C. jejuni ciaD mutant has reduced
MAP kinase signaling. (A) Maximal activation of MAP kinase signaling
requires CiaD. The activation status of the MAP kinase signaling
components was determined using a phospho-spot array assay as
outlined in Supplemental Methods (Additional file 1). INT 407 cells were
infected with the C. jejuni wild-type strain and C. jejuni ciaD mutant for 3
hr. Cellular lysates were assayed using the spot array. Pictured are the
spot array profiles of the C. jejuni wild-type and C. jejuni ciaD mutant. (B)
Maximal activation of MAP kinase signaling requires CiaD. Densitometry
was performed on the phospho-spot arrays performed in Panel B.
Significance was not assessed, as this experiment was used as a screen
for activation.
Additional file 8: Figure S8. The CiaD ΔMKD site and Δ(S/T)P proteins
are synthesized and the isolates that produce these variant proteins are
motile. (A) Deletion of the MKD site and the (S/T)P site does not
significantly effect protein synthesis. The C. jejuni ciaD mutant
transformed with a pRY111 vector encoding either a wild-type copy of
the CiaD protein, the MAP kinase docking motif (ΔMKD site) mutant
protein, or the (Δ(S/T)P) mutant protein fused to a FLAG-tag were
analyzed by immunoblot analysis. The blots were probed with a FLAG
antibody. Blots were also stripped and re-probed with an anti-CysM
antibody to ensure equal loading of each sample. (B) C. jejuni strains
synthesizing the CiaD MAP kinase docking motif (ΔMKD site) mutant
protein and CiaD proline directed-phosphorylation site (Δ(S/T)P) mutant
protein are motile.
Additional file 9: Figure S9. C. jejuni colonization of IL10-/- mice. (A)
Percent survival of C57BL/6 IL-10-/- mice infected with the C. jejuni 11168
wild-type strain, ciaD mutant, and the ciaD complemented isolate. No
significant differences were observed in the number of surviving mice as
judged by Kaplan Meier log rank analysis. The mouse inoculated with the
C. jejuni ciaD complemented isolate that died 8 days post-infection was
excluded from the gross pathology evaluation (Figure 7A), as the cause
of death was not known. (B) Colonization of mice infected with the C.
jejuni wild-type strain, ciaD mutant, and the ciaD complement isolate was
assessed 35 days post-infection by bacterial CFU determination of colon
content and Campylobacter PCR on DNA extracted from frozen cecal tips
of all mice that were negative by culture.
Additional file 10: Figure S10. C. jejuni stimulates the production of
plasma IgG2b. Plasma IgG2b anti-C. jejuni antibody levels in mice infected
with a C. jejuni wild-type strain, ciaD mutant, and the ciaD
complemented isolate. Levels of IgG2B were evaluated via ELISA. We
found that the C. jejuni wild-type strain had a significant increase in the
amount of detectable IgG2b as judged by nonparametric Kruskal Wallis
one-way ANOVA, followed by post hoc comparisons using MannWhitney pairwise comparisons. Corrections were made for multiple
comparisons using the Holm-Šidák test.
Additional file 11: Table S1. Bacterial isolates and plasmids used in
this study.
Additional file 12: Table S2. Primers used in this study.
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